343 articles with Medivir AB
Medivir AB today announces that MIV-828 has been nominated as a candidate drug (CD) for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.
Increased focus where we can create the most value
Medivir AB announced today plans to reduce activities not critical to its development pipeline of drug candidates as part of its enhanced focus on clinical stage projects.
Medivir AB announced today its plans to concentrate its activities on clinical development.
Medivir AB today announced safety and efficacy data following an interim analysis of phase I data from the ongoing phase I/II study of birinapant in combination with MSD's anti-PD-1 therapy, Keytruda®.
Dr. Basse will report to CEO Christine Lind and join the Medivir Executive Team.
Investigator-initiated Phase II Clinical Study of Remetinostat Started in Patients With Basal Cell Carcinoma
edivir AB announced that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with basal cell carcinoma (BCC).
MIV-711 Osteoarthritis Phase IIa Extension Study Outcomes Show Continuing Positive Effect on Joint Structure
Medivir AB announces positive top-line joint structure outcomes from the MIV-711 osteoarthritis phase IIa extension study (MIV-711-202).
Successful progression of clinical projects
Medivir Announces Positive Top-line Results From the MIV-711 Osteoarthritis Phase IIa Extension Study
MIV-711 200mg had an acceptable safety and tolerability profile with 6 months of additional treatment with 200 mg MIV-711
Continued Discussions With FDA on Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
The start of the study will not be possible earlier than 2019, and thus not in 2018 as previously communicated.
Phase I/II Study Design of Birinapant in Combination With Keytruda® to be Presented on June 4 at the ASCO Annual Meeting
The poster presentation will be given by the study's lead investigator, Prof. Russell J. Schilder, Director of the Medical Gynecologic Oncology Program
Additional Remetinostat Phase II Data Will be Presented at the International Investigative Dermatology Meeting on May 18 and 19
The focus of the presentation is the effect of remetinostat on reducing pruritis (itching), as seen in the phase II study.
The annual general meeting in Medivir Aktiebolag (publ) on 3 May 2018 resolved to approve the profit and loss account and balance sheet as well as the consolidated profit and loss account and consolidated balance sheet for the financial year 2017.
Medivir AB announces that the number of shares and votes in Medivir has changed as a result of conversion of all class A shares to class B shares.
Medivir AB: Data From the MIV-711 Initial Phase IIa Study Will be Presented at the OARSI World Congress on April 27
Medivir AB (Nasdaq Stockholm: MVIR) today informs that data from the initial phase IIa study of MIV-711, which demonstrated disease-modifying activity in patients with moderate knee osteoarthritis after only six months of treatment, will be presented during the Osteoarthritis Research Society International (OARSI) World Congress, which will take place from 26-29 April 2018 in Liverpool, UK.
Medivir AB announces that the prospectus, which has been prepared as a result of the conversion of all class A shares in Medivir to class B shares, is now available on Medivir's website, www.medivir.se.
Medivir - The Nomination Committee´s Proposal for New Board of Directors to the Annual General Meeting 2018
Medivir AB announces the Nomination Committee's proposal for a new Board of Directors to the Annual General Meeting 2018.
Medivir AB announced that John Öhd, Chief Medical Officer at Medivir, has decided to leave the company.
The Extraordinary General Meeting in Medivir on 26 January 2018 resolved, among other things, on the following.